204 related articles for article (PubMed ID: 7529014)
1. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
2. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.
Buckheit RW; Hollingshead MG; Germany-Decker J; White EL; McMahon JB; Allen LB; Ross LJ; Decker WD; Westbrook L; Shannon WM
Antiviral Res; 1993 Jul; 21(3):247-65. PubMed ID: 7692815
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
4. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
Buckheit RW; Germany-Decker J; Hollingshead MG; Allen LB; Shannon WM; Janssen PA; Chirigos MA
AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1097-106. PubMed ID: 7508723
[TBL] [Abstract][Full Text] [Related]
5. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
6. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
7. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
[TBL] [Abstract][Full Text] [Related]
9. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
10. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.
Kashman Y; Gustafson KR; Fuller RW; Cardellina JH; McMahon JB; Currens MJ; Buckheit RW; Hughes SH; Cragg GM; Boyd MR
J Med Chem; 1992 Jul; 35(15):2735-43. PubMed ID: 1379639
[TBL] [Abstract][Full Text] [Related]
11. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
12. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
McMahon JB; Gulakowski RJ; Weislow OS; Schultz RJ; Narayanan VL; Clanton DJ; Pedemonte R; Wassmundt FW; Buckheit RW; Decker WD
Antimicrob Agents Chemother; 1993 Apr; 37(4):754-60. PubMed ID: 7684215
[TBL] [Abstract][Full Text] [Related]
13. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.
Witvrouw M; Arranz ME; Pannecouque C; Declercq R; Jonckheere H; Schmit JC; Vandamme AM; Diaz JA; Ingate ST; Desmyter J; Esnouf R; Van Meervelt L; Vega S; Balzarini J; De Clercq E
Antimicrob Agents Chemother; 1998 Mar; 42(3):618-23. PubMed ID: 9517942
[TBL] [Abstract][Full Text] [Related]
14. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
De Clercq E; Yamamoto N; Pauwels R; Baba M; Schols D; Nakashima H; Balzarini J; Debyser Z; Murrer BA; Schwartz D
Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5286-90. PubMed ID: 1608936
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV michellamines from Ancistrocladus korupensis.
Boyd MR; Hallock YF; Cardellina JH; Manfredi KP; Blunt JW; McMahon JB; Buckheit RW; Bringmann G; Schäffer M; Cragg GM
J Med Chem; 1994 Jun; 37(12):1740-5. PubMed ID: 8021914
[TBL] [Abstract][Full Text] [Related]
17. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Stup TL; Pyle CA; White EL; McMahon JB; Currens MJ; Boyd MR
Antiviral Res; 1995 Mar; 26(2):117-32. PubMed ID: 7541618
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Rösner M; Rübsamen-Waigmann H; Kaiser R; Wichers M; Schneweis KE
Antimicrob Agents Chemother; 1995 Oct; 39(10):2253-7. PubMed ID: 8619578
[TBL] [Abstract][Full Text] [Related]
19. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
